Demannose

Demannose

SCHEMBL2799182

O=C[C@H](O)[C@@H](O)[C@H](O)CO.O=C[C@H](O)[C@@H](O)[C@H](O)CO.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
TDP1 Q9NUW8 1/20 0.52
PDE4A P27815 1/20 0.44
AKR1B1 P15121 1/20 0.42
USP2 O75604 1/20 0.41
SLCO1B1 Q9Y6L6 1/20 0.41
KDM4E B2RXH2 2/20 0.39
MPI P34949 1/20 0.34
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
TOP1 P11387 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Demannose SCHEMBL3904983 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL6750831 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Galactose SCHEMBL14856251 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL8528284 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Galactose SCHEMBL1548813 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL22712624 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL6055085 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL461962 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL20817166 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL1858493 1.00 LMNA (0.55) LMNAL3MBTL1TDP1PDE4AAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017025566-A1 IMPROVED RECOMBINANT FACTOR VII GLYCOTOPE GMBH (DE) 2017-02-16 WO claimed
US-10844110-B2 O-linked glycoforms of polypeptides and method to manufacture them NOVO NORDISK HEALTHCARE AG (CH) 2020-11-24 US disclosed
EP-1745141-B2 O-LINKED GLYCOFORMS OF FAKTOR VII AND METHOD TO MANUFACTURE THEM NOVO NORDISK HEALTHCARE AG (CH) 2019-09-25 EP disclosed
US-20180057566-A1 O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them NOVO NORDISK HEALTHCARE AG (CH) 2018-03-01 US disclosed
WO-2017025566-A1 IMPROVED RECOMBINANT FACTOR VII GLYCOTOPE GMBH (DE) 2017-02-16 WO disclosed
US-9023992-B2 Hydrophobic interaction chromatography purification of factor VII polypeptides NOVO NORDISK HEALTHCARE AG (CH) 2015-05-05 US disclosed
US-20110064719-A1 HYDROPHOBIC INTERACTION CHROMATOGRAPHY PURIFICATION OF FACTOR VII POLYPEPTIDES NOVO NORDISK A/S (DK) 2011-03-17 US disclosed
EP-1745141-B1 O-LINKED GLYCOFORMS OF FAKTOR VII AND METHOD TO MANUFACTURE THEM NOVO NORDISK HEALTHCARE AG (CH) 2010-01-20 EP disclosed
US-20080305518-A1 O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them NOVO NORDISK HEALTHCARE A/G (CH) 2008-12-11 US disclosed
EP-1952822-A1 Factor VII polypeptides with increased affinity to platelets NOVO NORDISK A/S (DK) 2008-08-06 EP disclosed
WO-2008090215-A1 FACTOR VII POLYPEPTIDES WITH INCREASED AFFINITY TO PLATELETS NOVO NORDISK HEALTH CARE AG (DK) 2008-07-31 WO disclosed
US-20070037966-A1 Hydrophobic interaction chromatography purification of factor VII polypeptides NOVO NORDISK A/S (DK) 2007-02-15 US disclosed
EP-1745141-A1 O-LINKED GLYCOFORMS OF POLYPEPTIDES AND METHOD TO MANUFACTURE THEM Novo Nordisk Health Care AG (CH) 2007-01-24 EP disclosed
WO-2005111225-A1 O-LINKED GLYCOFORMS OF POLYPEPTIDES AND METHOD TO MANUFACTURE THEM NOVO NORDISK HEALTH CARE AG (CH) 2005-11-24 WO disclosed